1
|
Landén M, Jonsson L, Klahn AL, Kardell M, Göteson A, Abé C, Aspholmer A, Liberg B, Pelanis A, Sparding T, Pålsson E. The St. Göran Project: A Multipronged Strategy for Longitudinal Studies for Bipolar Disorders. Neuropsychobiology 2025; 84:86-99. [PMID: 39746340 PMCID: PMC11965871 DOI: 10.1159/000543335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2024] [Accepted: 12/22/2024] [Indexed: 01/04/2025]
Abstract
INTRODUCTION The St. Göran Bipolar Project (SBP) is a longitudinal outpatient study investigation aimed at identifying predictive factors associated with long-term outcomes in individuals with bipolar disorder. These outcomes include cognitive function, relapse rate, treatment responses, and functional outcomes. The study employs a multifaceted approach, integrating brain imaging, biochemical analyses of cerebrospinal fluid and blood, and genetics. This paper provides an overview of the research methods used in the SBP, along with a summary of the main findings to date. METHODS SBP is a collaborative effort between academia and healthcare, enrolling study participants from bipolar outpatient clinics in Stockholm (SBP-S) and Gothenburg (SBP-G), Sweden. Healthy controls were recruited through Statistics Sweden. Data and samples were collected using structured interviews, self-rated questionnaires, blood and cerebrospinal fluid samples, magnetic resonance imaging, and neuropsychological tests. Follow-up visits are conducted 7 and 14 years after baseline. CONCLUSION The SBP has generated numerous original findings and has contributed to advancing knowledge on cognitive function, personality, cerebrospinal and blood biomarkers, neuroimaging, and genetics. Further, as data collection nears completion, new research questions can be addressed. The study's strengths include detailed, multimodal information from each study visit and a long follow-up period. The naturalistic setting ensures that findings are relevant to real-world scenarios. However, variability in data completeness can introduce selection bias. Additionally, the control population, while randomly selected, may not be fully representative due to the voluntary nature of participation. Future projects will focus on longitudinal analyses and novel methods to exploit the study's multifaceted approach. INTRODUCTION The St. Göran Bipolar Project (SBP) is a longitudinal outpatient study investigation aimed at identifying predictive factors associated with long-term outcomes in individuals with bipolar disorder. These outcomes include cognitive function, relapse rate, treatment responses, and functional outcomes. The study employs a multifaceted approach, integrating brain imaging, biochemical analyses of cerebrospinal fluid and blood, and genetics. This paper provides an overview of the research methods used in the SBP, along with a summary of the main findings to date. METHODS SBP is a collaborative effort between academia and healthcare, enrolling study participants from bipolar outpatient clinics in Stockholm (SBP-S) and Gothenburg (SBP-G), Sweden. Healthy controls were recruited through Statistics Sweden. Data and samples were collected using structured interviews, self-rated questionnaires, blood and cerebrospinal fluid samples, magnetic resonance imaging, and neuropsychological tests. Follow-up visits are conducted 7 and 14 years after baseline. CONCLUSION The SBP has generated numerous original findings and has contributed to advancing knowledge on cognitive function, personality, cerebrospinal and blood biomarkers, neuroimaging, and genetics. Further, as data collection nears completion, new research questions can be addressed. The study's strengths include detailed, multimodal information from each study visit and a long follow-up period. The naturalistic setting ensures that findings are relevant to real-world scenarios. However, variability in data completeness can introduce selection bias. Additionally, the control population, while randomly selected, may not be fully representative due to the voluntary nature of participation. Future projects will focus on longitudinal analyses and novel methods to exploit the study's multifaceted approach.
Collapse
Affiliation(s)
- Mikael Landén
- Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Lina Jonsson
- Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
| | - Anna Luisa Klahn
- Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
| | - Mathias Kardell
- Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
| | - Andreas Göteson
- Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
| | - Christoph Abé
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Quantify Research, Stockholm, Sweden
| | | | - Benny Liberg
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | | | - Timea Sparding
- Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
| | - Erik Pålsson
- Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
| |
Collapse
|
2
|
Camprodon-Boadas P, De Prisco M, Rabelo-da-Ponte FD, Sugranyes G, Clougher D, Baeza I, Torrent C, Castro-Fornieles J, Tosetti Y, Vieta E, de la Serna E, Amoretti S. Cognitive reserve and cognition in mood disorders: A systematic review and meta-analysis. Psychiatry Res 2024; 339:116083. [PMID: 39003801 DOI: 10.1016/j.psychres.2024.116083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 02/21/2024] [Accepted: 07/09/2024] [Indexed: 07/16/2024]
Abstract
Cognitive functioning heterogeneity is a well-recognized phenomenon in individuals diagnosed with mood disorders. Cognitive Reserve (CR) has been linked to multiple positive outcomes, including cognitive performance in these patients. This systematic review and meta-analysis aim to provide a comprehensive analysis of the relationship between CR and cognitive functioning in individuals with mood disorders, including bipolar disorder and depressive disorders. Following PRISMA guidelines, a systematic review and meta-analysis was conducted of original research exploring the relationship between CR and cognitive performance in adult individuals with mood disorders. The literature search was conducted on PubMed, Scopus, and Web of Science, from 2002 to September 2023, and the Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of studies. Overall, 17 studies met the inclusion criteria for the systematic review and 11 for the meta-analysis. Both qualitative and quantitative findings suggested a positive relationship between CR measures and cognitive domains. CR emerges as a possible protective factor for cognitive functioning in adult individuals with mood disorders, potentially helping to mitigate the cognitive impairments associated with the disorder. These findings underscore the importance of the fact that promoting and enhancing CR could help in the cognitive prognosis of this population.
Collapse
Affiliation(s)
- Patricia Camprodon-Boadas
- Department of Child and Adolescent Psychiatry and Psychology, 2021SGR01319, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Spain; Fundació de Recerca Clínic Barcelona-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Department of Medicine, Institute of Neuroscience, University of Barcelona, Spain.
| | - Michele De Prisco
- Fundació de Recerca Clínic Barcelona-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Francisco Diego Rabelo-da-Ponte
- Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom
| | - Gisela Sugranyes
- Department of Child and Adolescent Psychiatry and Psychology, 2021SGR01319, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Spain; Fundació de Recerca Clínic Barcelona-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
| | - Derek Clougher
- Fundació de Recerca Clínic Barcelona-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain; BIOARABA, Department of Psychiatry. Hospital Universitario de Alava. University of the Basque Country, Vitoria, Spain
| | - Inmaculada Baeza
- Department of Child and Adolescent Psychiatry and Psychology, 2021SGR01319, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Spain; Fundació de Recerca Clínic Barcelona-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Department of Medicine, Institute of Neuroscience, University of Barcelona, Spain
| | - Carla Torrent
- Fundació de Recerca Clínic Barcelona-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Josefina Castro-Fornieles
- Department of Child and Adolescent Psychiatry and Psychology, 2021SGR01319, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Spain; Fundació de Recerca Clínic Barcelona-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Department of Medicine, Institute of Neuroscience, University of Barcelona, Spain
| | - Yamila Tosetti
- Department of Child and Adolescent Psychiatry and Psychology, 2021SGR01319, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
| | - Eduard Vieta
- Fundació de Recerca Clínic Barcelona-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Elena de la Serna
- Department of Child and Adolescent Psychiatry and Psychology, 2021SGR01319, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
| | - Silvia Amoretti
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Department of Psychiatry, Hospital Universitari Vall d'Hebron, Group of Psychiatry, Mental Health and Addictions, Psychiatric Genetics Unit, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
| |
Collapse
|
7
|
Karantonis JA, Rossell SL, Carruthers SP, Sumner P, Hughes M, Green MJ, Pantelis C, Burdick KE, Cropley V, Van Rheenen TE. Cognitive validation of cross-diagnostic cognitive subgroups on the schizophrenia-bipolar spectrum. J Affect Disord 2020; 266:710-721. [PMID: 32056949 DOI: 10.1016/j.jad.2020.01.123] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2019] [Revised: 12/03/2019] [Accepted: 01/20/2020] [Indexed: 12/14/2022]
Abstract
BACKGROUND Cognitive heterogeneity in schizophrenia spectrum disorders (SSD) and bipolar disorder (BD) has been explored using clustering analyses. However, the resulting subgroups have not been cognitively validated beyond measures used as clustering variables themselves. We compared the emergent cross-diagnostic subgroups of SSD and BD patients on measures used to classify them, and also across a range of alternative cognitive measures assessing some of the same constructs. METHOD Domain scores from the Matrics Consensus Cognitive Battery were used in a cross-diagnostic clustering analysis of 86 patients with SSD (n = 45) and BD (n = 41). The emergent subgroups were then compared to each other and healthy controls (n = 76) on these and alternative measures of these domains, as well as on premorbid IQ, global cognition and a proxy of cognitive decline. RESULTS A three-cluster solution was most appropriate, with subgroups labelled as Globally Impaired, Selectively Impaired, and Superior/Near-Normal relative to controls. With the exception of processing speed performance, the subgroups were generally differentiated on the cognitive domain scores used as clustering variables. Differences in cognitive performance among these subgroups were not always statistically significant when compared on the alternative cognitive measures. There was evidence of global cognitive impairment and putative cognitive decline in the two cognitively impaired subgroups. LIMITATIONS For clustering analysis, sample size was relatively small. CONCLUSIONS The overall pattern of findings tentatively suggest that emergent cross-diagnostic cognitive subgroups are not artefacts of the measures used to define them, but may represent the outcome of different cognitive trajectories.
Collapse
Affiliation(s)
- James A Karantonis
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia
| | - Susan L Rossell
- Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia; St Vincent's Mental Health, St Vincent's Hospital, VIC, Australia
| | - Sean P Carruthers
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia
| | - Philip Sumner
- Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia
| | - Matthew Hughes
- Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia
| | - Melissa J Green
- School of Psychiatry, University of New South Wales (UNSW), Sydney, NSW, Australia; Neuroscience Research Australia, Randwick, NSW, Australia
| | - Christos Pantelis
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; Florey Institute of Neuroscience and Mental Health, Melbourne, Australia; Department of Electrical and Electronic Engineering, University of Melbourne, VIC, Australia; Centre for Neuropsychiatric Schizophrenia Research (CNSR) and Centre for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, Glostrup, Denmark
| | - Katherine E Burdick
- Harvard Medical School, Department of Psychiatry, Boston, MA, United States; Brigham and Women's Hospital, Boston, MA, United States
| | - Vanessa Cropley
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia
| | - Tamsyn E Van Rheenen
- Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Melbourne, Australia; Centre for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne University, Melbourne, Australia.
| |
Collapse
|
11
|
Valvassori SS, Dal-Pont GC, Resende WR, Varela RB, Peterle BR, Gava FF, Mina FG, Cararo JH, Carvalho AF, Quevedo J. Lithium and Tamoxifen Modulate Behavior and Protein Kinase C Activity in the Animal Model of Mania Induced by Ouabain. Int J Neuropsychopharmacol 2017; 20:877-885. [PMID: 29020306 PMCID: PMC5737643 DOI: 10.1093/ijnp/pyx049] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2017] [Accepted: 08/04/2017] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The intracerebroventricular injection of ouabain, a specific inhibitor of the Na+/K+-adenosine-triphosphatase (Na+/K+-ATPase) enzyme, induces hyperactivity in rats in a putative animal model of mania. Several evidences have suggested that the protein kinase C signaling pathway is involved in bipolar disorder. In addition, it is known that protein kinase C inhibitors, such as lithium and tamoxifen, are effective in treating acute mania. METHODS In the present study, we investigated the effects of lithium and tamoxifen on the protein kinase C signaling pathway in the frontal cortex and hippocampus of rats submitted to the animal model of mania induced by ouabain. We showed that ouabain induced hyperlocomotion in the rats. RESULTS Ouabain increased the protein kinase C activity and the protein kinase C and MARCKS phosphorylation in frontal cortex and hippocampus of rats. Lithium and tamoxifen reversed the behavioral and protein kinase C pathway changes induced by ouabain. These findings indicate that the Na+/K+-ATPase inhibition can lead to protein kinase C alteration. CONCLUSIONS The present study showed that lithium and tamoxifen modulate changes in the behavior and protein kinase C signalling pathway alterations induced by ouabain, underlining the need for more studies of protein kinase C as a possible target for treatment of bipolar disorder.
Collapse
Affiliation(s)
- Samira S Valvassori
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo).,Correspondence: S. S. Valvassori, PhD, Laboratório de Sinalização Neural e Psicofarmacologia, Programa de Pós-Graduação em Ciências da Saúde, Unidade Acadêmica em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, SC, Brasil, CEP 88806-000 ()
| | - Gustavo C Dal-Pont
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo)
| | - Wilson R Resende
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo)
| | - Roger B Varela
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo)
| | - Bruna R Peterle
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo)
| | - Fernanda F Gava
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo)
| | - Francielle G Mina
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo)
| | - José H Cararo
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo)
| | - André F Carvalho
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo)
| | - João Quevedo
- Laboratory of Neuronal Signaling and Psychopharmacology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, and Ms Gava); Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Valvassori, Mr Dal-Pont, Dr Resende, Mr Varela, Ms Peterle, Ms Gava, Ms Mina, and Dr Quevedo); Laboratory of Inborn Errors of Metabolism, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil (Dr Cararo); Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil(Dr Carvalho); Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo);Center of Excellence on Mood Disorders, Department of Psychiatry and BehavioralSciences, The University of Texas Health Science Center at Houston Medical School, Houston, Texas (Dr Quevedo); Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas (Dr Quevedo)
| |
Collapse
|